Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

471
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
471
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.8K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.8K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

200
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
200
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

607
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
607
Tumor Immunotherapy01:27

Tumor Immunotherapy

665
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
665
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

489
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
489

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atopic Dermatitis Across the Lifespan: Understanding, Measuring and Minimizing Cumulative Life Course Impairment.

Acta dermato-venereologica·2026
Same author

Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.

The Journal of dermatological treatment·2026
Same author

ProtekDuo in Lung Transplant Candidates: Insights From a Single-Center Study of Cases.

Annals of thoracic surgery short reports·2026
Same author

Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years.

The Journal of dermatological treatment·2026
Same author

Development of a Patient Decision Aid for Atopic Dermatitis Systemic Treatments in Adults.

JAMA dermatology·2026
Same author

Primary Cutaneous Cribriform Apocrine Carcinoma: A Case Report and Narrative Review.

BioMed (Basel, Switzerland)·2026
Same journal

Innovations and Emerging Therapies in Atopic Dermatitis Part 1.

Current treatment options in allergy·2025
Same journal

Drug-Induced Kounis Syndrome: Latest Novelties.

Current treatment options in allergy·2023
Same journal

Updates and Recent Advances on Venom Immunotherapy.

Current treatment options in allergy·2023
Same journal

Dance Is a Healing Art.

Current treatment options in allergy·2023
Same journal

New Biomarkers in Anaphylaxis (Beyond Tryptase).

Current treatment options in allergy·2022
Same journal

New Challenges in Drug Allergy: the Resurgence of Excipients.

Current treatment options in allergy·2022
See all related articles

Related Experiment Video

Updated: Sep 16, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K

Innovations and Emerging Therapies in Atopic Dermatitis Part 2.

Robyn Okereke1, Eric Simpson1

  • 1Department of Dermatology, Oregon Health and Sciences University, 3303 S Bond Ave Building 1, 16th Floor, Portland, OR 97239, USA.

Current Treatment Options in Allergy
|July 9, 2025
PubMed
Summary
This summary is machine-generated.

Novel topical therapies offer improved efficacy and safety for atopic dermatitis (AD) treatment, addressing drawbacks of older medications. Future research should extend long-term data for optimized topical AD management.

Keywords:
Atopic DermatitisEmerging therapyInnovationsTargeted therapyTopical therapyTopicals eczema

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.8K

Related Experiment Videos

Last Updated: Sep 16, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.3K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.1K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.8K

Area of Science:

  • Dermatology
  • Pharmacology
  • Immunology

Background:

  • Atopic dermatitis (AD) management has seen significant advancements.
  • Systemic therapies for AD have evolved, with a focus now shifting to topical treatments.
  • Traditional topical therapies for AD have limitations that newer treatments aim to overcome.

Purpose of the Study:

  • To review novel aspects of topical therapies for atopic dermatitis (AD).
  • To compare and discuss lapses in current topical therapy research for AD.
  • To present advances in topical therapies for AD, following a review of systemic therapies.

Main Methods:

  • Literature review focusing on recent developments in topical AD treatments.
  • Analysis of studies comparing novel and traditional topical therapies.
  • Evaluation of real-world and long-term data on topical AD therapies.

Main Results:

  • Recent evolution in topical therapy options for AD.
  • Emergence of novel, molecularly targeted topical therapies.
  • These targeted therapies show potential to overcome drawbacks of traditional topical medicines.

Conclusions:

  • The shift towards targeted topical AD therapies is linked to enhanced efficacy and safety.
  • Improved patient compliance is a noted benefit of newer topical treatments.
  • Future studies need to extend long-term data to optimize topical AD therapy.